A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

This study is testing a new cell therapy using specially activated natural killer (NK) cells — a type of immune cell — to treat blood cancers (AML, MDS, or related conditions) that have come back or not gone away after a stem cell transplant from a donor. **You may be eligible if...** - You have AML, MDS (including juvenile MML), or a related bone marrow cancer that has relapsed or persisted after a donor stem cell transplant - Your disease is measurable by bone marrow testing or other methods - You have been off immune-suppressing medications for at least 2 weeks, and it is at least 2 months since your last transplant - Both adult and pediatric patients may be eligible **You may NOT be eligible if...** - You are in severe organ failure or have active, uncontrolled infection - You have active graft-versus-host disease (GVHD) requiring treatment - You are pregnant or breastfeeding - You are currently on high-dose immune-suppressing medications Talk to your doctor to see if this trial is right for you.